Pandemic Treatment Access and Affordability Act of 2021
Latest action · Mar 22, 2021 Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJan 28, 2021
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Pandemic Treatment Access and Affordability Act of 2021
This bill imposes licensing and price restrictions on federally supported drugs and other medicines intended to address COVID-19 (i.e., coronavirus disease 2019) or other public health emergencies.
With respect to a COVID-19 drug patent developed using certain types of federal support, any license granted by the federal government shall be open and nonexclusive. Similarly, a licensee or assignee for such a patent shall grant open nonexclusive licenses for the patent. An entity that receives a license shall pay reasonable royalties to (1) the patent holder, or (2) the owner of marketing exclusivity rights granted by the Food and Drug Administration (FDA) that were terminated under this bill.
The bill requires that such drugs be offered at a fair and reasonable price based on certain considerations, such as access.
If the Department of Health and Human Services (HHS) finds that the price of any drug to address a public health emergency is excessive, HHS must void any FDA-granted exclusivity for the drug and grant open and nonexclusive licenses to other manufacturers. Such licenses are subject to reasonable royalty requirements.
Cosponsors 26
Members who signed on, in the order they did. Signatures ran from Jan 28, 2021 to May 28, 2021; 14 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-MN | Betty McCollum | Original | Jan 28, 2021 |
| D-ME | Chellie Pingree | Original | Jan 28, 2021 |
| D-DC | Eleanor Holmes Norton | Original | Jan 28, 2021 |
| D-MD | Jamie Raskin | Original | Jan 28, 2021 |
| D-CA | Judy Chu | Original | Jan 28, 2021 |
| D-TX | Lloyd Doggett | Original | Jan 28, 2021 |
| D-WI | Mark Pocan | Original | Jan 28, 2021 |
| D-OR | Peter A. DeFazio | Original | Jan 28, 2021 |
| D-VT | Peter Welch | Original | Jan 28, 2021 |
| D-WA | Pramila Jayapal | Original | Jan 28, 2021 |
| D-AZ | Raúl M. Grijalva | Original | Jan 28, 2021 |
| D-CA | Ro Khanna | Original | Jan 28, 2021 |
| D-CT | Rosa L. DeLauro | Original | Jan 28, 2021 |
| D-GA | Sanford D. Bishop, Jr. | Original | Jan 28, 2021 |
| D-FL | Alcee L. Hastings | Feb 22, 2021 | |
| D-IN | André Carson | Feb 22, 2021 | |
| D-PA | Dwight Evans | Feb 22, 2021 | |
| D-CA | Mark DeSaulnier | Feb 22, 2021 | |
| D-GU | Michael F. Q. San Nicolas | Feb 22, 2021 | |
| D-FL | Al Lawson, Jr. | Feb 23, 2021 | |
| D-NV | Dina Titus | Feb 23, 2021 | |
| D-PA | Mary Gay Scanlon | Feb 23, 2021 | |
| D-CT | Jahana Hayes | Mar 26, 2021 | |
| D-TN | Steve Cohen | Mar 26, 2021 | |
| D-NC | David E. Price | May 4, 2021 | |
| D-MS | Bennie G. Thompson | May 28, 2021 |
Committees 4
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Jan 28, 2021 |
| Health Subcommittee | Referred Feb 2, 2021 | |
| House | Judiciary Committee | Referred Jan 28, 2021 |
| Courts, Intellectual Property, Artificial Intelligence, and the Internet Subcommittee | Referred Mar 22, 2021 | |
| House | Science, Space, and Technology Committee | Referred Jan 28, 2021 |
| House | Armed Services Committee | Referred Jan 28, 2021 |
Actions 4
Everything that happened, newest first.
- Mar 22, 2021Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
- Feb 2, 2021Referred to the Subcommittee on Health.
- Jan 28, 2021Introduced in House
- Jan 28, 2021Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 167, no. 17, January 28, 2021, page H252.
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 7296 | MMAPPP Act of 2020 | Reintroduction of | Jun 22, 2020 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To require any COVID-19 drug developed in whole or in part with Federal support to be affordable and accessible by prohibiting monopolies and price gouging, and for other purposes.
- Short Title(s) as Introduced
- Pandemic Treatment Access and Affordability Act of 2021
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Business records
- Cardiovascular and respiratory health
- Civil actions and liability
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Emergency medical services and trauma care
- Fraud offenses and financial crimes
- Government information and archives
- Health
- Health care costs and insurance
- Health programs administration and funding
- Health promotion and preventive care
- Health technology, devices, supplies
- Immunology and vaccination
- Income tax credits
- Infectious and parasitic diseases
- Inflation and prices
- Intellectual property
- Manufacturing
- Medical tests and diagnostic methods
- Minority health
- Public contracts and procurement
- Research and development
- User charges and fees
Text 1
Each version as it was printed, newest first.
- Jan 28, 2021Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
